Date: Tuesday 9 December 2025
Time: 11:30 – 12:00 CET
Location: Online
Exploring the first year of the HTAR implementation. We share essential insights, highlight key learnings, and outline the next steps shaping the future of market access. Perfect for market access professionals who need clarity and actionable guidance for their upcoming JCA activities going into 2026.
This webinar explored:
-
- Delivering clarity on the developments that defined the first year under the EU HTA regulation.
- Revealing how national HTA and P&R frameworks evolved to integrate JCAs in 2025.
- Empowering success in JCA amid dynamic global changes in 2026.
We joined leading experts and industry voices as we unpacked the implications, forecasted emerging trends, and discussed strategic responses from a European perspective.
Speakers
- Sebastian Vinzens, Senior Medical Writer, Germany
- Claire Blaney, Director, Market Access & Pricing Strategy, Ireland
- Maud Brijs, Medical & Market Access Manager, BeNeLux
Kintiga (formerly MAP Patient Access, AxTalis & SKC) is Europe’s leading independent specialist pharmaceutical and biotechnology management consultancy. Our mission is to partner with health technology developers to elevate client capabilities and expand European market access.
We provide strategic consulting services to optimise market access, commercialisation, and regulatory success, ensuring innovative treatments reach more European patients faster.
Our varied webinar programme aims to shine a spotlight on key developments in the market access sphere and share actionable approaches to alleviate some of the pain points that health technology developers face in their everyday work.
